Till now, breast cancer patients were being served with a so-called good and effective combination of bevacizumab and capecitabine but the same are not the recommendations of the recently drafted guidance especially for the NHS patients.
Yes, the new draft guidance from the National Institute for Health and Clinical Excellence (NICE) is not at all supporting the first-line treatment that till date was being suggested to every patient suffering from metastatic breast cancer.
According to statements revealed by the healthcare guidance body for England and Wales, no NHS patients must be given the treatment of bevacizumab (brand name Avastin) and chemotherapy drug capecitabine because they are not beneficial for this stage of the disease.
Statements coming from the institute's appraisal committee said that no evidences have been provided by the drug's manufacturer showing the effective effect upon the patient's health. Moreover, the evidences also proved that the treatment did not properly utilize the NHS resources.
The committee members saw no evidence proving any betterment in the patient's health. Also, doubts still existed if the treatment could increase the overall survival rate or no.
Explaining their side, the institute's Chief Executive, Sir Andrew Dillon, said, "We can't recommend a drug that has not been shown to work as well as, or better than, current treatments and costs much more. Bevacizumab has so far not been proven to be clinically or cost-effective".
The researchers mark all the treatments important for the medical industry. Also, these form a base of any patient's life then risking patients intentionally with an ineffective treatment will ditch medical norms.
The NICE some weeks earlier had also banned introduction of a separate drug called eribulin (Halaven) for the treatment of secondary breast cancer in patients, who have already underwent chemotherapy.